Scaling Up Cell & Gene Therapy Supply Chains
      
    
   
  
  
      
    
      
        
          Presented by AIM, the strategic leader in life science supply chains
        
       
     
    
  
  
      
    
      
        
          
            Transitioning from clinical stage to commercial is just the start. This paper explores how cell & gene supply chains must always evolve as a company matures.